Predicting Suboptimal Ruxolitinib Response in Myelofibrosis: Lessons To Be Learned from the POIESIS Trial

Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.

In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.

Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

Hagop Kantarjian, MD, discusses the arsenal of TKIs approved for chronic myeloid leukemia and how to navigate them regarding treatment selection.

Priya Rastogi, MD, discusses findings from a sub-study of the GeparDouze trial evaluating the effects of ctDNA positivity on treatment outcomes in TNBC.

Christian Grommes, MD, and Ashley Sumrall, MD, FACP, FASCO, discuss the phase 3 IGNITE trial of tirabrutinib in PCNSL.

Callisia N. Clarke, MD, MS, FACS, FSSO, discusses how earlier alignment between surgeons and medical oncologists on systemic therapy use allows more patients to undergo resection.